2007
DOI: 10.1111/j.1365-2265.2007.02836.x
|View full text |Cite
|
Sign up to set email alerts
|

Variation in GH and IGF‐I assays limits the applicability of international consensus criteria to local practice

Abstract: SummaryBackground There is increasing reliance on consensus criteria for decision making. Recent criteria state that acromegaly is excluded by a nadir GH during an oral glucose tolerance test (OGTT) of < 1 µ g/l and a normal level of IGF-I. Objective To study GH and IGF-I assay performance close to cut-off values for active acromegaly. Design and methods Two serum samples known to give borderline results were sent to all centres participating in the UK National External Quality Assessment Service (NEQAS). Samp… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
88
0
4

Year Published

2008
2008
2022
2022

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 154 publications
(95 citation statements)
references
References 31 publications
3
88
0
4
Order By: Relevance
“…Active ACM is associated with elevated IGF1 levels compared to normal subjects (Ho & Weissberger 1994), so a normal IGF1 (using age-and sex-matched reference ranges) excludes the diagnosis in most patients (Katznelson et al 2014). However, certain pathological conditions (see Table 3), assay variability or inaccurate reference ranges (Pokrajac et al 2007) can lead to false negative results, especially in mild cases.…”
Section: Diagnosismentioning
confidence: 99%
“…Active ACM is associated with elevated IGF1 levels compared to normal subjects (Ho & Weissberger 1994), so a normal IGF1 (using age-and sex-matched reference ranges) excludes the diagnosis in most patients (Katznelson et al 2014). However, certain pathological conditions (see Table 3), assay variability or inaccurate reference ranges (Pokrajac et al 2007) can lead to false negative results, especially in mild cases.…”
Section: Diagnosismentioning
confidence: 99%
“…This study utilized the Nichols GH ILMA that is no longer commercially available. Taking into account the heterogeneity of assay performance (9,17,30,31), our estimates of the false-negative rate of GHn value in patients with relatively low spontaneous GH output may not be numerically applicable to the currently used GH assays. Similar studies utilizing GH assays currently in clinical and research use are needed.…”
Section: Discussionmentioning
confidence: 99%
“…Einige Probleme der weit verbreiteten IGF-I-Assays ä hneln denen der GH-Assays [23] : Viele Methoden sind nach wie vor mit einer schlecht charakterisierten, wenig reinen Referenzpr ä paration kalibriert [39] , obwohl klinische wie labormedizinische Fachgesellschaften den Einsatz der neuen rekombinanten Referenzpr ä paration 02/254 fordern [22] . F ü r IGF-I sind 6 hochaffi ne Bindungsproteine beschrieben, von denen insbesondere das IGFBP-3 aufgrund seiner hohen Konzentration im Serum eine erhebliche Herausforderung f ü r die Messverfahren darstellt.…”
Section: Insulinartiger Wachstumsfaktor I (Insulin-like Growth-factorunclassified